Autres langues Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Temps réel estimé Cboe BZX Autres places de cotation 18:57:17 29/04/2024			Varia. 5j.	Varia. 1 janv.
6,97 ^USD	-3,73%		+1,83%	-2,16%

24/04	Pasithea Therapeutics Corp. annonce que la première cohorte a terminé le dosage initial dans son essai de phase 1 évaluant Pas-004 dans les cancers mutés Ras, Nf1 et Raf	CI
29/03	Pasithea Therapeutics Corp. présente ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	13:59
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	24/04
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	24/04
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	13/02
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	13/02
Top Premarket Decliners	12/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	09/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application	02/01
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	28/12
Pasithea Therapeutics Announces Results from 2023 Annual Meeting	19/12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	11/12
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	29/11
Pasithea Therapeutics Gets Positive Response From FDA Meeting for Rare Cancer Treatment	29/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Autres langues

Filtres